Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.36 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.36 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.36 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.36 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3826929 | 0.99 | KDM1A (0.42) | KDM1APDE3BPDE3ACYP1A2CYP11B1 | |
| SCHEMBL17004234 | 0.77 | CHRNA7 (0.42) | KDM1ACHRNA7 | |
| SCHEMBL745239 | 0.76 | KDM1A (0.47) | KDM1APDE3BPDE3ACYP1A2CYP11B1 | |
| SCHEMBL29604064 | 0.76 | KCNH2 (0.47) | MAP3K11PDE10ACHRNA7 | |
| SCHEMBL17004276 | 0.76 | KCNH2 (0.47) | MAP3K11PDE10ACHRNA7 | |
| SCHEMBL748520 | 0.76 | KDM1A (0.45) | KDM1APDE3BPDE3ACYP1A2CYP11B1 | |
| Hydrochloric Acid SCHEMBL746931 | 0.75 | KDM1A (0.45) | KDM1APDE3BPDE3ACYP1A2CYP11B1 | |
| SCHEMBL17004244 | 0.73 | CHRNA7 (0.43) | CHRNA7 | |
| SCHEMBL17004213 | 0.69 | CHRNB2 (0.41) | CHRNA7 | |
| SCHEMBL17004264 | 0.68 | CHRNB2 (0.39) | CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | claimed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | claimed |
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2013-04-18 | — | — | US | claimed |
| EP-2099795-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | Abbott Laboratories (US) | 2009-09-16 | — | — | EP | claimed |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | claimed |
| WO-2008058096-A9 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LAB (US) | 2008-06-26 | — | — | WO | claimed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | claimed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8314119-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2012-11-20 | — | — | US | disclosed |
| EP-2099795-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | Abbott Laboratories (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | ABBOTT LABORATORIES (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008058096-A9 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LAB (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096132-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | KDM1A 406/4885PDE3B 91/4885PDE3A 57/4885 |
| US-20080167336-A1 | Alzheimer's disease; central nervous system disorders; aids; Pick's disease; attention deficit disorder; hyperactivity; Down's syndrome, amytropic lateral sclerosis; Huntington's disease; suppression of smoking; drug abruse; brain disorders; analgesics; antiinflammatory agents | HTT, ACHE, CHRNA10 | KDM1A 1596/4885PDE3B 1796/4885PDE3A 971/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | KDM1A 406/4885PDE3B 91/4885PDE3A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.